Apellis Pharmaceuticals Inc (APLS)
35.41
+0.43
(+1.23%)
USD |
NASDAQ |
Jul 03, 16:00
Apellis Pharmaceuticals Net Income (Annual): -528.63M for Dec. 31, 2023
Net Income (Annual) Chart
Historical Net Income (Annual) Data
Date | Value |
---|---|
December 31, 2023 | -528.63M |
December 31, 2022 | -652.17M |
December 31, 2021 | -746.35M |
December 31, 2020 | -344.87M |
December 31, 2019 | -304.71M |
December 31, 2018 | -127.50M |
Date | Value |
---|---|
December 31, 2017 | -51.01M |
December 31, 2016 | -27.12M |
December 31, 2015 | -46.52M |
December 31, 2014 | -10.79M |
December 31, 2013 | -3.962M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Annual) Range, Past 5 Years
-746.35M
Minimum
2021
-304.71M
Maximum
2019
-515.35M
Average
-528.63M
Median
2023
Net Income (Annual) Benchmarks
Blueprint Medicines Corp | -506.98M |
Alnylam Pharmaceuticals Inc | -440.24M |
Cytokinetics Inc | -526.24M |
Amicus Therapeutics Inc | -151.58M |
Insmed Inc | -749.57M |